INTRODUCTION
Although angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) and β-blockers reduce morbidity and mortality in patients with heart failure due to left ventricular systolic dysfunction, there is evidence that these treatments are underused, particularly in primary care. [1] [2] [3] [4] [5] Some patients who should receive these medications do not and many receive less than evidence-based doses. [2] [3] [4] [5] Pharmacists may play a role in improving treatment through "collaborative medication review", a process in which the pharmacist evaluates a patient's medications and suggests changes which are enacted with the agreement of the patient and the family doctor. 6-9 A meta-analysis of small, short-term, trials and observational data suggest that this intervention reduces the risk of hospital admission and possibly mortality in patients with heart failure studied in a secondary care setting. 6- 10 We conducted a larger-scale, longer-term, prospective randomised controlled trial to test the hypothesis that a low-cost, low-intensity, pharmacist intervention to optimise medical treatments, particularly ACE inhibitors, ARBs, and β-blockers, in patients identified in primary care with left ventricular systolic dysfunction would reduce the composite outcome of hospital admission for worsening heart failure or death, as well as other clinically important outcomes.
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METHODS
Study design and patients
The study was conducted within the National Health Service (NHS) which provides free health care to the population of the United Kingdom. The design of our trial has been published and was consistent with Consolidated Standards of Reporting Trials. [11] [12] [13] Consenting patients were eligible if aged 18 years or older and had left ventricular systolic dysfunction confirmed by cardiac imaging conducted at a local hospital (transthoracic echocardiography in 90% of cases). Patients did not have to have symptoms or signs of heart failure. Family doctors receive a semi-quantitative report of left ventricular systolic function (normal; mild, moderately or severely reduced) instead of ejection fraction. A key exclusion criterion was registration with the heart failure-nurse service which is provided to patients in our Health Board area recently admitted to hospital with heart failure. This criterion excluded higher risk patients with more severe symptoms. Other exclusion criteria included concurrent disease other than heart failure likely to reduce life-expectancy; severe cognitive impairment or psychiatric illness; dialysis, or a resident in a long-term care facility. The study was approved by the local ethics committee. All practices and patients gave written informed consent. The study is registered, number ISRCTN70118765.
Randomisation
We used a cluster-randomisation design as this provides protection against contamination across trial groups when trial patients are managed within the same setting as was the case in this study. Patients in practices in the UK are managed by all general practitioners within the practice; as the control intervention was mediated by general practitioners, this precluded 6 individual patient level randomisation. Family practices were randomly allocated using a third-party automated telephone interactive voice response system in a 1:1 ratio to receive intervention or usual care. Stratification was by socioeconomic deprivation (affluent, intermediate or deprived) at practice level, and practice-type (single-handed or grouppractice).
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Study procedures
The intervention was delivered by 27 primary care-based pharmacists employed by the NHS to work with family doctors and directly with patients to promote rational, cost-effective prescribing. 14 All participating pharmacists had between three and 16 years of postqualification experience. All had experience delivering primary care based medication review clinics for patients receiving multiple drug treatment. Seven pharmacists held postgraduate clinical pharmacy qualifications. Four pharmacists had hospital (ward-based) clinical pharmacy experience. Prior to commencing the intervention, all pharmacists attended one, inhouse training day (contact time 7.5 hours) covering the aetiology, symptoms and evidencebased management of heart failure. The day was co-ordinated by three pharmacists who had a special interest in heart failure therapeutics, and a general practitioner with a special interest in heart failure. The day comprised of a mixture of didactic teaching and interactive role-play
sessions. An additional mandatory three-hour session covered the methods of the trial. All pharmacists received an information pack with directed, heart failure-specific reading to supplement their training.
As part of routine continuing professional development, each pharmacist participated in a 3.5
hour peer-led session every month which involved group-discussion of cases encountered in their medication-review clinics. As the study pharmacists were embedded within primary 7 care practices, informal discussion on therapeutics occurred regularly between pharmacists, general practitioners and nurses within the practice. There was also regular telephone-contact between study pharmacists and the principal investigator or another pharmacist with a special interest in heart failure.
Patients from practices assigned to the intervention were offered a 30 minute appointment with a pharmacist. 
Study outcomes
The primary outcome was the composite of death from any cause or hospital admission for worsening heart failure, analysed as time to first event. We also compared the prescribing of medications between the intervention and usual care groups and evaluated health-care utilisation, other than admissions, at one and two years of follow-up e.g. the number of primary care contacts and hospital emergency room visits.
Statistical analysis
The trial data were managed and analysed by the Robertson Centre for Biostatistics, University of Glasgow. The primary analysis compared the main outcomes between the intervention and control groups using a Cox proportional hazards frailty model, which accounted for the cluster-randomisation design. [11] [12] [13] These analyses were adjusted for the stratification variables and the following variables of prognostic importance: age, creatinine, grade of left ventricular systolic dysfunction, atrial fibrillation, respiratory disease, total number of medical treatments, and diuretic use.
We initially assumed the rate of the primary outcome would be 10% per year in the control group and pharmacist intervention would lead to a relative risk reduction of 26%, based upon the known benefits of initiating disease-modifying treatment and of higher doses of those therapies. 1, 19, 20 Due to the cluster-randomisation design, the sample size needed to be increased by a factor of 1.55. [11] [12] [13] Consequently 87 practices (1044 patients) were required in each group. Blinded review of patient data in September 2010 suggested that 750 patients 9 would experience a primary outcome event at follow-up, providing 80% power to detect a 19% relative risk reduction with the intervention.
Logistic regression models were used to examine secondary outcomes including whether patients started or stopped a medical treatment or had a change in dose.
Safety was evaluated by examining hospital admissions for: symptomatic hypotension, collapse or syncope; renal dysfunction, failure or impairment; hyperkalaemia; asthma or chronic obstructive pulmonary disease; and bradycardia, atrioventricular block or pacemaker implantation. Fisher's exact t-test was used to compare the intervention group with the usual care group.
RESULTS
Study patients
All general practices in our locality were approached and 174 of 220 (79%) The two groups were balanced with respect to baseline characteristics ( Although general practitioners do not routinely record New York Heart Association (NYHA) class in our area (and NYHA class was not recorded by the study pharmacists) this measure was documented in the records of 337 patients; 85 (25%) were NYHA class I; 219 (65%)
were NYHA class II; 30 (9%) were NYHA class III and 3 (1%) were in NYHA class IV.
Very few (1.7%) patients had been admitted to hospital for heart failure in the year prior to randomisation.
Medical treatment
In each treatment group, approximately 86% of patients were receiving an ACE inhibitor, ARB or both (Table 1) and of these patients, 55% received 100% or more of the recommended dose. The proportion of patients receiving a β-blocker was 62% in each treatment group. Of these, 21% were treated with 100% or more of the recommended dose (Table 1) .
Patients not prescribed an ACE inhibitor, ARB or β-blocker, or not prescribed the recommended doses of these medications at baseline, were potentially eligible for treatment optimisation. Table 2 shows the effect of pharmacist intervention (patients who died during the first and second years of follow-up were excluded from this analysis -dead patients could not receive the intervention). Pharmacist intervention during the first year of the trial led to a greater frequency of initiation of an ACE inhibitor or ARB and a β-blocker, compared with usual care ( respectively. These differences were sustained during the second year with no evidence of "catch-up" prescribing in the usual care group (see Supplementary data). There was no difference between treatment-groups regarding dose-reduction, or discontinuation of these drugs. The proportion of patients collecting 80% or more of prescriptions (from their general practice) was 99% in the pharmacist intervention group versus 99% in the usual care group for ACE inhibitors, 98% versus 98% for ARBs and 98% versus 99% for beta-blockers (no difference between treatment groups for any drug).
At the end of year 1, 5.0% of the pharmacist intervention group and 4.6% in the usual care group were prescribed an aldosterone antagonist. At the end of year 2 the proportions were 5.1% and 5.2%.
At baseline diltiazem or verapamil was used in 132 (6%) of patients, a non-steroidal antiinflammatory drug in 144 (7%), an anti-depressant in 223 (10%) [a tricyclic in 73 (3%)] and a glitazone in 17 (1%). These drugs were discontinued more often in the pharmacist intervention group in the first year but the difference in rates of discontinuation between the two treatment groups were not statistically significant (see Supplementary data).
Study outcomes
Death from any cause or hospital admission for heart failure (the primary outcome) occurred in 390 patients (35.8%) in the intervention group and 380 patients (35.4%) in the usual care group ( Figure 2 and Table 4 ). The adjusted hazard ratio [HR] for the primary outcome in the intervention group, as compared to the usual care group, was 0.97, 95% CI 0.83-1.14, p=0.72). The effect of the intervention on this outcome was consistent in an unadjusted analysis (Table 4) and across all pre-specified subgroups (Figure 3 ). The number of patients admitted to hospital for any reason, for a cardiovascular cause and for heart failure was similar in the two treatment groups ( Findings for the other pre-specified secondary outcomes and safety outcomes are reported in the Supplementary data.
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DISCUSSION
Although a meta-analysis of small, short-term, studies suggested that pharmacist intervention improves clinical outcomes in patients with heart failure 7 , we did not confirm this in a much larger and longer trial conducted in primary care, despite the intervention leading to improvements in the use of disease-modifying medications which persisted for at least two years.
There are a number of possible explanations for this finding. The frequency of use of ACE inhibitors and ARBs at baseline was greater than reported in previous studies in primary care, and even in our pilot study, with 86% of patients prescribed at least one of these medications. [2] [3] [4] [5] 21 The explanation for this unexpected finding is uncertain although in 2004, the year our trial started, the United Kingdom government introduced a new contract for family doctors linking pay to performance.
22,23
Prescribing of ACE inhibitors (but not β-blockers) in patients with left ventricular systolic dysfunction was one of the incentivised activities. As a consequence of the high baseline use of ACE inhibitors and ARBs, there was little scope to initiate these agents. There was also limited opportunity to increase the dose of these drugs as a high proportion (55%) of subjects was already receiving the recommended dose at baseline. Furthermore, dose was increased in only about a third of eligible patients in the intervention group (compared with 19% of those in the usual care group), presumably because of tolerability and safety considerations, perhaps indicating that the rate of use and dosing of these drugs may have already approached a ceiling level. Certainly, the rate of use of ACE inhibitors and ARBs and the doses that they were used at in our trial equal or exceed those in recent heart failure trials (despite our patients being more elderly than in these other trials) 24, 25 and a national audit in the United Kingdom 26 .
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Although there was more scope to improve β-blocker prescribing, initiation of this type of medication and increase in dose of β-blocker was infrequent in both treatment groups. This lack of success may indicate that the brief period of tuition used to prepare the non-specialist pharmacists in our trial was insufficient. Unfamiliarity with the use of β-blockers, and persisting concerns about their tolerability and safety, in left ventricular systolic dysfunction amongst family doctors at the time our trial started, as well as the high prevalence of respiratory disease in our population may also have limited β-blocker use. Additionally, patients may also have been unwilling to take an additional medication given the high rate of multi-drug regimens in the population studied (47% were receiving more than 8 medications). Nevertheless, although the rate of use of beta-blockers was disappointing, the proportion of patients taking 100% or more of the recommended dose of beta-blocker by the end of the first year in the pharmacist intervention group (26%) compared favourably with the Systolic Heart failure treatment with I f inhibitor ivabradine Trial (SHIFT) where this proportion was 26% at baseline. 24 A second explanation for the lack of effect of our intervention was the relatively low frequency of hospital admission for heart failure which meant that the majority of events contributing to the primary composite outcome were fatal. In addition, only half of the deaths that occurred were attributed to cardiovascular causes. We excluded high-risk patients under the care of specialist heart failure nurses. Furthermore, falling hospital admission rates for heart failure have been reported in several countries 15, [27] [28] [29] [30] [31] and, recently, cardiovascular deaths, as a proportion of overall deaths, have also been reported to be declining in patients with heart failure. 32 Consequently, there were fewer non-fatal and fatal events which might have been reduced through greater use of ACE inhibitors, ARBs and β-blockers. We believe that these two factors -only a modest improvement in use of disease-modifying treatment 16 coupled with a low rate of modifiable events -are the most likely explanation for a lack of improvement in clinical outcomes in our trial.
The low rate of use of aldosterone antagonists in our trial was due to the exclusion of more severely ill patients who were under the care of the specialist heart failure nurse service and hospital clinics. At the time of our trial aldosterone antagonists were only indicated in such patients. 1 Clearly, if such a trial were repeated today, use of aldosterone antagonists would be encouraged by pharmacists.
Potentially harmful medications e.g. rate-limiting calcium channel blockers, non-steroidal anti-inflammatory drugs, tricyclic antidepressants, oral corticosteroids and glitazones were prescribed in a very small proportion of patients at baseline and pharmacist intervention did not lead to any greater discontinuation of these medicines, as compared with usual care during follow-up.
As explained in the Methods section, we had to use a cluster randomisation design. We ensured good internal validity by accounting for the clustered nature of the data in our sample size calculations and ensuring blinding to allocation status of those recruiting individuals into the trial and good external validity by providing information on numbers approached, recruited and lost to follow-up. We therefore followed best practices in relation to this type of trial. Furthermore, although a major limitation of this design is lack of similarity of the study groups, our treatment groups were well matched.
12,13
There were several limitations to our trial. The study pharmacists were not trained to elicit signs and symptoms of heart failure. We did not collect reasons why patients might have been ineligible for a specific treatment or unable to tolerate it (collecting this information on the control group might have caused contamination). Ejection fraction was not reported to general practitioners and natriuretic peptides measurements were not available in primary care at the time our patients were recruited. Although our trial did not achieve its goal of improving clinical outcomes it did demonstrate that modest and sustained improvements in the prescribing of disease-modifying medications can be achieved by a brief, focused, collaborative intervention delivered by non-specialist pharmacists given only a short period of training. However, the short period of training and brevity of intervention may also have been limitations of our study. This was particularly true in relation to beta-blockers where our intervention had a disappointingly small effect on the use of these drugs. Lessons for future trials may be that more intense training, more patient visits and selective involvement of hospital specialists might be required to fully optimise treatment. It is also possible that modification of other treatments that we didn't target, such as diuretics may have improved outcome and this could also be examined in future studies. While this type of intervention may not benefit all patients, it might improve clinical outcomes if aimed at those in most need in terms of deficient background treatment or at those at higher risk of modifiable events. This is a question that may be considered in future comparative-effectiveness trials.
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Figure 1 Study Recruitment
Figure 2
Main Study Outcomes
Figure 3
Sub-group analysis for the primary outcome. 
